{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:55:45Z","timestamp":1791896145660,"version":"4.3.4"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","award":["CUP E63C22001680001\\u2014ID T4-AN-04"],"award-info":[{"award-number":["CUP E63C22001680001\\u2014ID T4-AN-04"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.biopha.2025.118621","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:45:00Z","timestamp":1759538700000},"page":"118621","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Modelling-filtered drug repurposing and first-in-protein SPR validation of histone deacetylase 4 inhibitors for Ataxia-telangiectasia"],"prefix":"10.1016","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5683-079X","authenticated-orcid":false,"given":"Alessia","family":"Distefano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6623-2849","authenticated-orcid":false,"given":"Matteo","family":"Pappalardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Turco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7179-4835","authenticated-orcid":false,"given":"Giuseppe","family":"Grasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9858-7732","authenticated-orcid":false,"given":"Salvatore","family":"Guccione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2025.118621_bib1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13023-016-0543-7","article-title":"Ataxia telangiectasia: a review","volume":"11","author":"Rothblum-Oviatt","year":"2016","journal-title":"Orphanet. J. Rare Dis."},{"issue":"5","key":"10.1016\/j.biopha.2025.118621_bib2","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/nm.2709","article-title":"Nuclear accumulation of HDAC4 in ATM deficiency promotes neurodegeneration in ataxia telangiectasia","volume":"18","author":"Li","year":"2012","journal-title":"Nat. Med"},{"issue":"10","key":"10.1016\/j.biopha.2025.118621_bib3","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrm2514","article-title":"Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer","volume":"9","author":"Lavin","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118621_bib4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrm3546","article-title":"The ATM protein kinase: regulating the cellular response to genotoxic stress, and more","volume":"14","author":"Shiloh","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118621_bib5","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0168-9525(03)00073-8","article-title":"Class II histone deacetylases: versatile regulators","volume":"19","author":"Verdin","year":"2003","journal-title":"Trends Genet"},{"key":"10.1016\/j.biopha.2025.118621_bib6","unstructured":"Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases | PNAS [Internet]. [cited 2025 Aug 3]. Available from: \u3008https:\/\/www.pnas.org\/doi\/abs\/10.1073\/pnas.0706487104\u3009."},{"key":"10.1016\/j.biopha.2025.118621_bib7","unstructured":"Structural and Functional Analysis of the Human HDAC4 Catalytic Domain Reveals a Regulatory Structural Zinc-binding Domain - ScienceDirect [Internet]. [cited 2025 Aug 3]. Available from: \u3008https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0021925820524125\u3009."},{"issue":"4","key":"10.1016\/j.biopha.2025.118621_bib8","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/jcb.22185","article-title":"Histone deacetylase inhibitors: potential in cancer therapy","volume":"107","author":"Marks","year":"2009","journal-title":"J. Cell Biochem"},{"key":"10.1016\/j.biopha.2025.118621_bib9","unstructured":"HDAC4: Mechanism of Regulation and Biological Functions: Epigenomics: Vol 6, No 1 [Internet]. [cited 2025 Aug 3]. Available from: \u3008https:\/\/www.tandfonline.com\/doi\/abs\/10.2217\/epi.13.73\u3009."},{"key":"10.1016\/j.biopha.2025.118621_bib10","unstructured":"Drug repositioning: identifying and developing new uses for existing drugs | Nature Reviews Drug Discovery [Internet]. [cited 2025 Aug 3]. Available from: \u3008https:\/\/www.nature.com\/articles\/nrd1468\u3009."},{"issue":"7607","key":"10.1016\/j.biopha.2025.118621_bib11","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/534314a","article-title":"Can you teach old drugs new tricks?","volume":"534","author":"Nosengo","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118621_bib12","unstructured":"Orphan designation: Overview | European Medicines Agency (EMA) [Internet]. 2009 [cited 2025 Aug 3]. Available from: \u3008https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/orphan-designation-overview\u3009."},{"key":"10.1016\/j.biopha.2025.118621_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114141","article-title":"Identification of a novel adiponectin receptor and opioid receptor dual acting agonist as a potential treatment for diabetic neuropathy","volume":"158","author":"Ma","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.biopha.2025.118621_bib14","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev-physchem-032511-143716","article-title":"DEER distance measurements on proteins","volume":"63","author":"Jeschke","year":"2012","journal-title":"Annu Rev. Phys. Chem."},{"issue":"17","key":"10.1016\/j.biopha.2025.118621_bib15","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1007\/s00216-022-04122-3","article-title":"An SPR-based method for hill coefficient measurements: the case of insulin-degrading enzyme","volume":"414","author":"Distefano","year":"2022","journal-title":"Anal. Bioanal. Chem."},{"issue":"4","key":"10.1016\/j.biopha.2025.118621_bib16","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00249-008-0384-y","article-title":"Enzyme solid-state support assays: a surface plasmon resonance and mass spectrometry coupled study of immobilized insulin degrading enzyme","volume":"38","author":"Grasso","year":"2009","journal-title":"Eur. Biophys. J."},{"issue":"36","key":"10.1016\/j.biopha.2025.118621_bib17","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.2174\/0929867330666230116162646","article-title":"The use of surface plasmon resonance to study the interactions of proteins involved in conformational diseases: experimental approaches for new therapeutical perspectives","volume":"30","author":"Zingale","year":"2023","journal-title":"Curr. Med Chem."},{"issue":"7","key":"10.1016\/j.biopha.2025.118621_bib18","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrd838","article-title":"Optical biosensors in drug discovery","volume":"1","author":"Cooper","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.biopha.2025.118621_bib19","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd3027","article-title":"Asenapine","volume":"8","author":"Meltzer","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"issue":"D1","key":"10.1016\/j.biopha.2025.118621_bib20","doi-asserted-by":"crossref","first-page":"D932","DOI":"10.1093\/nar\/gkw993","article-title":"DrugCentral: online drug compendium","volume":"45","author":"Ursu","year":"2017","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"10.1016\/j.biopha.2025.118621_bib21","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/pr.57.4.2","article-title":"The evolution of iron chelators for the treatment of iron overload disease and cancer","volume":"57","author":"Kalinowski","year":"2005","journal-title":"Pharmacol. Rev."},{"issue":"4","key":"10.1016\/j.biopha.2025.118621_bib22","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1158\/0008-5472.CAN-12-2730","article-title":"Tasquinimod is an allosteric modulator of HDAC4 survival signaling within the compromised cancer microenvironment","volume":"73","author":"Isaacs","year":"2013","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.biopha.2025.118621_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103845","article-title":"Molecular medicinal insights into scaffold hopping-based drug discovery success","volume":"29","author":"Acharya","year":"2024","journal-title":"Drug Discov. Today"},{"issue":"2","key":"10.1016\/j.biopha.2025.118621_bib24","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1021\/ci050357s","article-title":"Molecular field extrema as descriptors of biological activity:\u2009definition and validation","volume":"46","author":"Cheeseright","year":"2006","journal-title":"J. Chem. Inf. Model"},{"issue":"6","key":"10.1016\/j.biopha.2025.118621_bib25","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1021\/acs.jmedchem.8b01925","article-title":"Electrostatic complementarity as a fast and effective tool to optimize binding and selectivity of Protein\u2013Ligand complexes","volume":"62","author":"Bauer","year":"2019","journal-title":"J. Med Chem."},{"issue":"6","key":"10.1016\/j.biopha.2025.118621_bib26","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1021\/acs.jcim.0c00165","article-title":"Assessment of binding affinity via alchemical Free-Energy calculations","volume":"60","author":"Kuhn","year":"2020","journal-title":"J. Chem. Inf. Model"},{"issue":"3","key":"10.1016\/j.biopha.2025.118621_bib27","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1006\/jmbi.1996.0897","article-title":"Development and validation of a genetic algorithm for flexible docking1","volume":"267","author":"Jones","year":"1997","journal-title":"J. Mol. Biol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118621_bib28","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/jcc.10379","article-title":"Converging free energy estimates: MM-PB(GB)SA studies on the protein\u2013protein complex Ras\u2013Raf","volume":"25","author":"Gohlke","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.biopha.2025.118621_bib29","unstructured":"Biacore T.200 Getting Started.book [Internet]. [cited 2025 Aug 3]. Available from: https:\/\/instruments.iitb.ac.in\/sites\/default\/files\/sop\/2024-12\/BiacoreT200_gettingstarted_handbook_IITB%20SPR%20Central%20Facility.pdf."},{"key":"10.1016\/j.biopha.2025.118621_bib30","unstructured":"HDAC4 \u2013 BioEntity: BE0003523 [Internet]. Available from: https:\/\/go.drugbank.com\/bio_entities\/BE0003523."},{"key":"10.1016\/j.biopha.2025.118621_bib31","doi-asserted-by":"crossref","unstructured":"Schasfoort R.B.M. Handbook of Surface Plasmon Resonance: 2nd Edition. Royal Society of Chemistry; 2017. 555 p.","DOI":"10.1039\/9781788010283"},{"issue":"1","key":"10.1016\/j.biopha.2025.118621_bib32","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.microc.2009.05.001","article-title":"Microfluidic networks for surface plasmon resonance imaging real-time kinetics experiments","volume":"93","author":"Grasso","year":"2009","journal-title":"Microchem J."},{"issue":"6","key":"10.1016\/j.biopha.2025.118621_bib33","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/j.1476-5381.2009.00604.x","article-title":"Ligand binding assays at equilibrium: validation and interpretation","volume":"161","author":"Hulme","year":"2010","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118621_bib34","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1021\/cr068107d","article-title":"Surface plasmon resonance sensors for detection of chemical and biological species","volume":"108","author":"Homola","year":"2008","journal-title":"Chem. Rev."},{"issue":"23","key":"10.1016\/j.biopha.2025.118621_bib35","doi-asserted-by":"crossref","first-page":"12173","DOI":"10.1039\/C9CP02261A","article-title":"Conformational dynamics and allosteric effect modulated by the unique zinc-binding motif in class IIa HDACs","volume":"21","author":"Liu","year":"2019","journal-title":"Phys. Chem. Chem. Phys."},{"issue":"31","key":"10.1016\/j.biopha.2025.118621_bib36","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.2174\/138161206778743600","article-title":"Biomolecular interaction analysis in drug discovery using surface plasmon resonance technology","volume":"12","author":"Huber","year":"2006","journal-title":"Curr. Pharm. Des."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225008157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225008157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:23:43Z","timestamp":1775780623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225008157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":36,"alternative-id":["S0753332225008157"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118621","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modelling-filtered drug repurposing and first-in-protein SPR validation of histone deacetylase 4 inhibitors for Ataxia-telangiectasia","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118621","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118621"}}